Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells 5,400 Shares of Stock

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) Director Kristina Burow sold 5,400 shares of the firm's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $29.72, for a total transaction of $160,488.00. Following the completion of the transaction, the director now owns 21,071 shares of the company's stock, valued at $626,230.12. This trade represents a 20.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Scholar Rock Price Performance

SRRK traded up $0.21 on Monday, reaching $29.22. The company had a trading volume of 164,220 shares, compared to its average volume of 1,265,774. The business has a 50 day simple moving average of $30.38 and a 200 day simple moving average of $36.10. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -12.50 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period in the previous year, the firm earned ($0.59) EPS. As a group, sell-side analysts anticipate that Scholar Rock Holding Co. will post -2.42 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wedbush reaffirmed an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $42.67.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Scholar Rock by 17.6% during the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock worth $205,013,000 after acquiring an additional 708,817 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of Scholar Rock during the fourth quarter worth approximately $274,000. Blackstone Inc. purchased a new position in shares of Scholar Rock during the fourth quarter worth approximately $910,000. Rhumbline Advisers raised its stake in shares of Scholar Rock by 13.2% during the fourth quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock worth $4,895,000 after acquiring an additional 13,247 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Scholar Rock during the fourth quarter worth approximately $2,625,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.